Literature DB >> 10334480

In vitro synaptotrophic effects of Cerebrolysin in NT2N cells.

M Mallory1, W Honer, L Hsu, R Johnson, E Rockenstein, E Masliah.   

Abstract

Recent studies have shown that Cerebrolysin can enhance synaptic function and ameliorate synaptodendritic alterations in animal models of neurodegeneration, suggesting a synaptotrophic effect. We hypothesize that Cerebrolysin might exert this effect, in part, by regulating the expression of amyloid precursor protein (APP). We studied the patterns of expression of synaptic proteins during differentiation of human teratocarcinoma cell line NTera 2 (NT2) in the presence or absence of Cerebrolysin. This study showed that the terminally differentiated neurons (NT2N) expressed a wide variety of synaptic markers and that expression of these synaptic-associated proteins coincided with the shift in expression from APP770/751 to APP695. Furthermore, APP immunoreactivity was colocalized with synaptophysin-immunoreactive neuritic varicosities in NT2N neurites, and Cerebrolysin treatment of NT2N cells resulted in an augmented and earlier expression of synaptic-associated proteins. This increased synaptic protein expression coincided with an increase in APP695 over APP770/751. These results support the possibility that synaptotrophic effects of Cerebrolysin might be mediated via regulation of APP expression.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10334480     DOI: 10.1007/s004010051012

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  6 in total

Review 1.  Cerebrolysin for stroke, neurodegeneration, and traumatic brain injury: review of the literature and outcomes.

Authors:  Brian Fiani; Claudia Covarrubias; Amelia Wong; Thao Doan; Taylor Reardon; Daniel Nikolaidis; Erika Sarno
Journal:  Neurol Sci       Date:  2021-01-30       Impact factor: 3.307

Review 2.  NO orchestrates the loss of synaptic boutons from adult "sick" motoneurons: modeling a molecular mechanism.

Authors:  Bernardo Moreno-López; Carmen R Sunico; David González-Forero
Journal:  Mol Neurobiol       Date:  2010-12-29       Impact factor: 5.590

3.  Beneficial effects of a neurotrophic peptidergic mixture persist for a prolonged period following treatment interruption in a transgenic model of Alzheimer's disease.

Authors:  Edward Rockenstein; Kiren Ubhi; Emiley Pham; Sarah Michael; Edith Doppler; Philipp Novak; Chandra Inglis; Michael Mante; Anthony Adame; X Anton Alvarez; Herbert Moessler; Eliezer Masliah
Journal:  J Neurosci Res       Date:  2011-07-25       Impact factor: 4.164

Review 4.  Cerebrolysin: a review of its use in dementia.

Authors:  Greg L Plosker; Serge Gauthier
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

5.  Neurotrophic effects of Cerebrolysin in the Mecp2(308/Y) transgenic model of Rett syndrome.

Authors:  Edith Doppler; Edward Rockenstein; Kiren Ubhi; Chandra Inglis; Michael Mante; Anthony Adame; Leslie Crews; Monika Hitzl; Herbert Moessler; Eliezer Masliah
Journal:  Acta Neuropathol       Date:  2008-07-04       Impact factor: 17.088

6.  Neurofibrillary and neurodegenerative pathology in APP-transgenic mice injected with AAV2-mutant TAU: neuroprotective effects of Cerebrolysin.

Authors:  Kiren Ubhi; Edward Rockenstein; Edith Doppler; Michael Mante; Anthony Adame; Christina Patrick; Margarita Trejo; Leslie Crews; Amy Paulino; Herbert Moessler; Eliezer Masliah
Journal:  Acta Neuropathol       Date:  2009-02-28       Impact factor: 17.088

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.